Mahzi Therapeutics

Advancing precision therapies for rare neurodevelopmental diseases

https://wefunder.com/mahzi.therapeutics

Total raised on Wefunder: 0

Total investors: 0

Quick facts

• $60M raised from leading VCs: Venrock, HealthCap, Droia Ventures & HBM Partners
• $16M in non-dilutive grant awards from the California Institute for Regenerative Medicine
• Leadership from Stanford, Cambridge, Yale, UC Berkeley & Weizmann Institute
• Close collaborations with Pitt Hopkins Foundation & many other patient advocacy groups
• CEO with 20+ years at Merck and rare disease pioneers Genzyme & Ultragenyx
• Now enrolling patients in first-ever gene therapy clinical trial for Pitt Hopkins Syndrome
• 800+ rare neurogenetic disorders addressable with our approach; targeting a $16B+ market
• $200-$600M peak annual revenue projected per indication in pipeline (not guaranteed)

Team profiles

• Yael Weiss
• Aaron Olsen

Featured investor profiles

• Vimal Srivastava